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Background & Motivation
Cerebrospinal fluid (CSF) analytes harbor potential as diagnostic biomarkers
for Alzheimer’s Disease (AD). Quantitative measures of CSF proteins comprise a
set of often highly correlated endophenotypes that have previously shown promise
in genetic analyses (Cruchaga et al., 2013; Kauwe et al., 2014). Pleiotropic im-
pact of genetic variations on this set may provide additional insights into AD
pathology at its earliest stages. To determine which specific endophenotypes are
pleiotropic, one can employ methods based on the reverse regression of genotype
on phenotypes. Recently, we proposed a method based on functional linear models
(Vsevolozhskaya et al, 2016) that utilizes reverse regression and simultaneously
evaluates all variants within a genetic region for an association with multiple cor-
related phenotypes. Here we apply our novel methodology to explore pleiotropic
eff ects of CSF analtyes using Alzheimer’s Disease Neuroimaging Initiative (ADNI)
data.
Materials
CSF levels of β-amyloid (Aβ) and τ proteins are potentially early diagnostic
markers for probable AD. We investigated the influence of genetic variation on
these markers for two candidate genes: APOE and CLU.
Data were obtained from the ADNI database. A total of 309 (AD = 79, MCI
= 148, NL = 82) individuals were included.
526 APOE single nucleotide polymorphism (SNP) and 569 CLU SNPs were
available for the analysis.
Normal (n = 82) Mean MCI (n = 148) Mean AD (n = 79) Mean
Age (year) 75.0 74.4 74.3
CSF Aβ levels (pg/ml) 205.5 161.9 144.9
CSF tau levels (pg/ml) 70.5 102.1 120.7
N N N
Male 45 101 44
Female 37 47 35
Table 1: Demogphic, clinical and biomarker data for ADNI subjects.
Methods
Our method is gene- or region-based. What makes it stand apart is the fact that a genetic
region serves as an outcome in the model, not a predictor (i.e., the so-called reverse regression).
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Figure 1: Smoothed allele counts within the APOE region for 309
subjects.
The genetic information does not enter the
model as discretized allele counts (e.g., 0, 1, 2)
but rather as a smooth function G(t), with t in-
dexing a genetic variants’ position over a genetic
region.
Fig. 1 illustrates genotypic functions fitted for
each subject, G(t),  = 1, . . .309, over the
APOE region.
Statistical Analysis
To examine the effect of SNPs on the 2 CSF biomarkers, we fit the following functional linear
model:
E [G(t)] = β0(t) + β1(t)XT + β2(t)XAbet + β3(t)Xε4
β4(t)XSe + β5(t)XAge + β6(t)XDg +
∑3
j=1β6+j(t)XPCj.
The model is looking for an association with a CSF biomarker, while adjusting for the level of
the other protein, gender, age and diagnosis status. Also, to ensure the significance is not due to
population stratification, we incorporated the top three principal components to further control
for the population structure.
Two analyses were performed: with APOE ε4 genotype (number of APOE ε4 alleles; 0, 1,
2) as a covariate and without.
The analysis is Bayesian; the estimated β̂j(t)’s are obtained as posterior expectations; the
confidence bands are obtained as 95% posterior crediable intervals.
Results: Exploring the estimated β̂T(t) and β̂Abet(t)
APOE: no ε4 adjustment
rs429358rs2075650
rs7412rs7254892
−0.1
0.0
0.1
SNP position
A
lle
le
 d
os
ag
e
Abeta Levels /  APOE Gene
Figure 2: Estimated posterior expectation of APOE association with
Aβ biomarker and the corresponding 95% credible intervals.
APOE genotype is the established risk
factor for LOAD. The two previously iden-
tified APOE SNPs (rs429358, rs7412)
that define the ε2/ε3/ε4 alleles for AD
susceptibility are among the top SNPs
that drive the association with the ele-
vated Aβ levels in our model. Addition-
ally, TOMM40/APOE rs7254892 that
was recently identified to be associated
with longer human longevity (Lin et al.,
2016) is clearly associated with lower Aβ
levels in our analysis. TOMM40/APOE
rs2075650 is also associated with lower
Aβ levels under the functional inference,
confirming prior report by Kim et al.,
2011.
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Figure 3: Estimated posterior expectation of APOE association with τ
biomarker and the corresponding 95% credible intervals.
Cervantes et al., 2011, tested APOE
rs79429216 and rs76214972 for an asso-
ciation with AD, but after multiple test
correction their allelic P-value were found
to be non-significant (0.747 and 0.053 re-
spectively). Nonetheless, in our analysis,
the credible interval for the genetic effect
of both of these SNPs does not capture
zero and they were found to be associated
with the elevated τ levels.
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Figure 4: Estimated posterior expectation over APOE after ε4 covariate adjustment.
The ε4 adjustment did not have a significant impact on the association between
τ levels and AD; for Aβ the region over APOE SNPs rs429358, rs7412 is not longer
significant. Nonetheless, the second interval still contains a statistically significant signal
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Figure 5: Estimated posterior expectation of CLU association with Aβ biomarker, τ biomarker and the corresponding 95% credible
intervals.
No CLU SNPs were found to be associated with Aβ levels
Two markers (rs7012010, rs7012217) are in the constellation of SNPs that are associ-
ated with the elevated τ levels. Both of these SNPs were previously reported
